BRAF and melanoma: It should also be noted that the current findings were obtained in SK-MEL-28 and B16-F10 models, and therefore cannot be extrapolated to all melanoma backgrounds; validation in genetically diverse human melanoma lines, particularly BRAF-mutant models, will be required before broader claims of shared metabolic vulnerability can be made (Aktary et al., 2023; Michielon et al., 2023).